MedTrace Logo

Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors

NCT06501183 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2024-07-15

No results posted yet for this study

Summary

This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of Anti-CDH17 CAR-T cell injection in patients with CDH17-positive advanced malignant solid tumors.

Conditions

  • CDH17-positive Advanced Malignant Solid Tumors

Interventions

BIOLOGICAL

Anti-CDH17 CAR-T cells

Anti-CDH17 CAR-T cell injection will be administered intravenously after lymphodepleting.

Sponsors & Collaborators

  • UTC Therapeutics Inc.

    collaborator INDUSTRY

  • Shanghai Pudong Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-08
Primary Completion
2025-05-30
Completion
2026-05-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06501183 on ClinicalTrials.gov